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Epilepsy is a group of disorders characterized by recurrent seizures, and is one of the most common neurological
conditions. The genetic basis of epilepsy is clear from epidemiological studies and from rare gene discoveries in
large families. The three major classes of epilepsy disorders are genetic generalized, focal and encephalopathic
epilepsies, with several specific disorders within each class. Advances in genomic technologies that facilitate
genome-wide discovery of both common and rare variants have led to a rapid increase in our understanding
of epilepsy genetics. Copy number variant and genome-wide association studies have contributed to our
understanding of the complex genetic architecture of generalized epilepsy, while genetic insights into the focal
epilepsies and epileptic encephalopathies have come primarily from exome sequencing. It is increasingly clear that
epilepsy is genetically heterogeneous, and novel gene discoveries have moved the field beyond the known
contribution of ion channels to implicate chromatin remodeling, transcriptional regulation and regulation of the
mammalian target of rapamycin (mTOR) protein in the etiology of epilepsy. Such discoveries pave the way for new
therapeutics, some of which are already being studied. In this review, we discuss the rapid pace of gene discovery
in epilepsy, as facilitated by genomic technologies, and highlight several novel genes and potential therapies.The genetic basis of epilepsy
Epilepsy is defined by recurrent, unprovoked seizures
due to abnormal, synchronized neuronal firing in the
brain. The condition affects up to 1 in 26 individuals in
the United States [1], making it one of the most com-
mon neurological conditions. Approximately 20–30 %
of epilepsy cases are caused by acquired conditions
such as stroke, tumor or head injury, but the remaining
70–80 % of cases are believed to be due to one or more
genetic factors [2]. Although the definition of epilepsy
suggests that it is a single disorder, it is more accurate
to describe epilepsy as a group of disorders with di-
verse etiologies and outcomes. There are many differ-
ent epilepsy syndromes that can be characterized by
the seizure type(s), age of onset, developmental status,
co-morbid features and etiology [3].
The epilepsies can be broadly grouped into three clas-
ses: genetic generalized epilepsy (GGE; formerly idio-
pathic generalized epilepsy); focal epilepsy; and epileptic
encephalopathy (EE). There are then several specific syn-
dromes within each class defined by differences in* Correspondence: hmefford@uw.edu
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terns, age of onset and disease progression. We will refer
to these as primary epilepsy disorders. The GGE syn-
dromes, characterized by generalized seizures that in-
volve both sides of the brain, include juvenile myoclonic
epilepsy and childhood absence epilepsy among others.
The GGEs tend to start in childhood or adolescence and
are usually associated with normal development and intel-
lect. Focal seizures originate in one hemisphere of the
brain. Examples of focal epilepsy syndromes are temporal
lobe epilepsy, autosomal dominant nocturnal frontal lobe
epilepsy (ADNFLE), and autosomal dominant epilepsy
with auditory features. The EEs are severe, early onset con-
ditions characterized by refractory seizures, developmental
delay or regression associated with ongoing epileptic activ-
ity, and generally poor prognosis. Dravet, Ohtahara and
West syndromes are some of the most well-studied EEs.
Importantly, epilepsy is often a co-morbid condition in in-
dividuals with intellectual disability (ID), autism or schizo-
phrenia and may be a feature of many metabolic
conditions and genetic syndromes. The focus of this review
will be on the primary epilepsies, but we will also highlight
some of the advances that increase our understanding of
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decades, but the first evidence of a genetic component
emerged from epidemiological studies that reported an
increased risk of epilepsy in relatives of affected individ-
uals [4, 5]. Studies of twins showed that monozygotic
twins have a higher concordance rate for both GGE and
focal epilepsy than dizygotic twins, supporting the hy-
pothesis that epilepsy has a genetic basis [6, 7]. Human
genetics approaches that applied linkage analysis and gene
mapping in large families in the 1990s yielded a steady
trickle of gene discoveries, beginning with the finding that
mutations in CHRNA4, encoding a subunit of the nicotinic
acetylcholine receptor, cause ADNFLE [8]. Mutations in
other genes encoding ion channels, such as KCNQ2 in be-
nign familial neonatal seizures [9] and SCN1A in Dravet syn-
drome [10], led to the “channelopathy” hypothesis, which
postulates that dysfunction or dysregulation of ion channels
is a common mechanism underlying epilepsy syndromes.
The emergence of genomic technologies, including
chromosome microarrays and next-generation sequen-
cing, has accelerated our understanding of the genetic
architecture of the epilepsies, and the trickle of gene dis-
coveries has increased to a flood. Importantly, these
largely unbiased approaches have led to gene discoveries
that expand our knowledge of critical pathways for epi-
leptogenesis beyond the ion channels, opening the door
for the development of novel therapies. These technolo-
gies have led to advances in understanding of the differ-
ent genomic and genetic architectures across all the
major classes of epilepsy, including uncovering a surpris-
ing overlap among seemingly different disorders. We will
discuss the major advances in epilepsy genomics and
genetics that have surfaced largely due to advances in
these technologies.
Copy number variants in epilepsy
Copy number variants (CNVs) are deletions and duplica-
tions of stretches of DNA ranging from 1 kilobase to an
entire chromosome. CNVs are an important source of
normal genomic variation, but some act as risk factors
or causes of disease. The development of chromosome
microarrays—which include comparative genomic
hybridization and SNP genotyping arrays—allowed
genome-wide screening for CNVs in large cohorts.
CNV studies have been carried out for GGE, focal
epilepsy and EE, revealing a clear role for CNVs in
each major class. Overall, rare CNVs, some of which
involve known disease genes, contribute to 5–10 % of
cases of childhood epilepsies [11, 12].
Most studies of GGE suggest a complex genetic archi-
tecture with oligogenic inheritance [13, 14]. A few highly
penetrant genetic risk variants have been identified, most
through candidate gene studies. A major breakthrough in
identifying genetic risk factors for GGE came with theapplication of genome-wide chromosome microarrays for
genome-wide CNV detection in large cohorts of patients,
the first of which revealed that large, recurrent deletions
at chromosomes 15q13.3, 16p13.11 and 15q11.2 are signifi-
cantly enriched in patients with GGE [15–18]. Each of
these microdeletions is consistently found in 0.5–1 % of
patients, with the 15q13 microdeletion conferring the
most significant risk for epilepsy (odds ratio of 68) [19].
Consistent with the complex genetic architecture of
the disorder, each deletion exhibits variable inherit-
ance patterns (de novo or inherited) and incomplete
penetrance [20]. The 15q13.3 deletion appears to be a
risk factor primarily for GGE, while the 15q11.2 and
16p13.11 deletions are also found in patients with
focal and other epilepsies [21]. Notably, all three dele-
tions are known risk factors for ID, autism and schizophre-
nia as well, highlighting a shared genetic susceptibility for
these disorders. Importantly, patients with GGE and ID
are more likely to have one of these three deletions than
patients with GGE and normal intellect [22]. Rare dele-
tions involving the exons of some neuronal genes have re-
cently been shown to increase risk for GGE, including
NRXN1 [23], RBFOX1 [24] and GPHN [25].
To our knowledge, the largest study of patients with
focal epilepsy carried out so far included 3812 affected
individuals [21]. The 16p13.11 deletion described above
was found in 23 cases (0.6 %). In addition, there was an
excess of large (>2 megabase) rare deletions in cases com-
pared to controls. In the EEs, pathogenic CNVs account
for approximately 3–5 % of cases [11, 26]. Interestingly,
deletions of 15q13.3, 15q11.2 and 16p13.11, important for
GGE and focal epilepsy, are rarely seen in patients with
EE, highlighting the notion that the major classes of epi-
lepsy have different genetic architectures [27]. Importantly,
identifying regions of overlap among non-recurrent dele-
tions in similarly affected patients can point to novel dis-
ease genes. This approach prompted targeted sequencing
of CHD2, a gene located in 15q26 deletions, and led to the
discovery that de novo mutations cause an EE character-
ized by myoclonic seizures, photosensitivity and
developmental delays [28, 29]. Targeted sequencing of
SLC6A1, one of two genes in a minimally deleted region of
3p25 microdeletions, led to the discovery of de novo muta-
tions in 4 % of patients with myoclonic astatic epilepsy
[30]. SLC6A1 encodes a GABA (γ-aminobutyric acid)
transporter responsible for reuptake of GABA from the
synapse. Conversely, the discovery of de novo mutations in
PURA in patients with EE helped define PURA as the crit-
ical gene in patients with 5q31.3 deletions [31, 32].
Genome-wide association studies
One of the earliest genomic approaches to complex dis-
ease was to perform genome-wide association studies
(GWASs), designed to identify common genetic variants
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been carried out for epilepsy, although most of the early
studies were too small to detect an effect or did not have
replicable results. A recent effort by the International
League Against Epilepsy produced a meta-analysis of 12
cohorts totaling >8000 cases with focal epilepsy or GGE
and >26,000 controls [33]. The analysis identified poly-
morphic sequence variants as risk factors for the com-
bined cohorts (focal and GGE) in SCN1A—perhaps the
most well—known epilepsy gene—and in protocadherin
7 (PCHD7), a gene not yet known to be associated with
epilepsy. In addition, when analyzing GGE alone, a signal
at chromosome 2p16.1 emerged and was narrowed down
to the interval containing the genes vaccinia-related kin-
ase 2 (VRK2) and Fanconi anaemia, complementation
group L (FANCL); there was no significant signal when
evaluating focal epilepsies alone. The results from this
study highlight the complex genetic architecture of focal
epilepsy and GGE and the need for continued investiga-
tion in even larger cohorts.
Another recent GWAS comes from Feenstra and col-
leagues, in which they identify common genetic variants
associated with risk for simple febrile seizures [34]. The
study compared children who had a febrile seizure after
receiving the measles–mumps–rubella (MMR) vaccine,
children who had febrile seizures unrelated to the MMR
vaccine, and controls without febrile seizures. Of four
risk loci identified for febrile seizures overall, two were
in well-known epilepsy genes (SCN1A and SCN2A). The
variant associated with the highest risk of febrile seizures
was in the anoctamin 3 (ANO3) gene, which encodes a
transmembrane protein that belongs to a family of chlor-
ide channels, and the fourth locus was an intergenic re-
gion on chromosome 12q21.33. A particularly interesting
aspect of this study was the identification of two variants,
one in the interferon-induced gene IFI44L and the other
in the measles virus receptor CD46, which are each spe-
cific for risk for febrile seizures after the MMR vaccine,
suggesting that we may someday be able to identify a sub-
set of children at risk for vaccine-related febrile seizures.
There have been no large GWASs performed for the
EEs. Although these severe disorders are thought to be
due largely to highly penetrant single-gene (or CNV)
mutations, it is possible that GWASs of unsolved cases
could reveal additional genetic risk factors.
Massively parallel sequencing in epilepsy
The advent of next-generation (massively parallel) se-
quencing technology has revolutionized gene discovery
in many disorders, including epilepsy. Applications of
next-generation sequencing include gene panel, whole-
exome and whole-genome sequencing. Gene panel and
whole-exome sequencing are used most frequently for
genetic testing in the clinic today and offer a rapid,affordable approach to mutation identification. Whole-
genome sequencing is primarily used in the research la-
boratory, but will inevitably enter the clinical realm for
diagnostics as it becomes more economical.
Perhaps the most significant recent advance in under-
standing the genetics of epilepsy has come from exome
sequencing in the EEs, the most severe group of epilep-
sies. Because of the severity of disease, cases are usually
sporadic with no other affected family members, pre-
cluding linkage analysis as a means to gene discovery.
The discovery in 2001 that de novo mutations in SCN1A
cause Dravet syndrome [10], one of the best-studied EEs,
set the stage for the de novo paradigm for this class of
disorders. Exome sequencing in single families and in
both small and large cohorts has proven to be an essential
tool to confirm the importance of de novo mutations, fa-
cilitate rapid gene discovery and highlight the genetic het-
erogeneity of this disorder. The major advances will be
highlighted here, as a comprehensive discussion of the dis-
coveries made is beyond the scope of this review.
In 2012, whole-genome sequencing in a single family
with a severely affected child revealed a de novo SCN8A
mutation in the proband [35]. Subsequent studies have
confirmed the importance of this gene in the etiology of
EE, with >25 cases reported with mutations in this gene
since 2013 [36–39]. Most patients have a similar clinical
presentation, with seizure onset at around five months of
age and subsequent developmental delays and ID. In a
slightly larger study, using exome sequencing in 39 pa-
tients with fever-associated epilepsies similar to Dravet
syndrome, Nava and colleagues identified two de novo
mutations in HCN1 [40]. Sequencing HCN1 in 157 add-
itional affected individuals yielded four more patients
with a mutation in this gene. HCN1 belongs to a family
of hyperpolarization-activated, cyclic-nucleotide-gated
channels that regulate neuronal excitability. Previous
studies suggested that rare variants in HCN1 and HCN2
are risk factors for GGE [41]. Another study of 13 un-
solved patients with Dravet syndrome revealed the im-
portance of mutations in GABRA1 and STXBP1 [42],
two genes previously implicated in other EEs. GABRA1
encodes the α1 subunit of the GABAA receptor, a multi-
subunit chloride channel that serves as the receptor for
the GABA inhibitory neurotransmitter. STXBP1 encodes
a syntaxin-binding protein that is critical for presynaptic
vesicle docking and fusion. Mutations in KCNB1, a
voltage-gated potassium channel, were also identified by
exome sequencing in three families [43]. Other examples
of recent gene discoveries are listed in Table 1.
Each of the discoveries described above adds to the
growing list of genes implicated in epilepsy, and most
support the channelopathy hypothesis. However, one of
the distinct advantages of whole-genome technologies is
the ability to use a hypothesis-free approach and discover
Table 1 Novel epilepsy gene discoveries from 2012 to 2015
Gene Phenotype(s) Number of casesa References
Chromatin remodeling
CHD2 EOEE, LGS, EE, ASD >20 [28, 44–46, 87]
Ion channels and neurotransmitter receptors
GABRA1 DS, IS, JME, CAE, GGE >10 [42, 46, 88–90]
GABRB3 IS, LGS 4 [46]
GRIN2A LKS, CSWS, BECTS, ABPE, EE >50 [91–97]
GRIN2B IS, LGS, FE/ID, ID, ASD >10 [46, 49, 54, 98]
HCN1 EOEE 4 [40]
KCNB1 IS 4 [43, 68]
KCNA2 EE 6 [99]
KCNC1 PME 13b [100]
KCNQ2 BFNS, EOEE, EE >50 [9, 72, 101–104]
KCNT1 MPSI, ADNFLE 14 [81, 105–108]
SCN8A EE, EOEE >30 [35, 37–39, 108]
SLC6A1 MAE 6 [30]
Intracellular signaling
GNAO1 OS, IS, EE 6 [68, 109]
SYNGAP1 EE, ID, ASD >20 [28, 54, 110, 111]
TBC1D24 MPSI, DOORS, EOEE, FE + ID, FIME, PME >15 [100, 112–118]
Metabolism
CERS1 PME 1a [119]
SLC13A5 EOEE 3a [120]
SLC25A22 NEESBs, MPSI, EME 4a [121–124]
SLC35A2 EOEE, IS 8 [68, 125, 126]
Synaptic vesicle cycle
DNM1 IS, LGS 5 [68]
NECAP1 EOEE 1a [127]
SNAP25 EE 1 [128]
STX1B Fever-associated epilepsy 6 [129]
STXBP1 EOEE, OS, IS, DS, EE >50 [42, 130–137]
mTOR signaling
DEPDC5 FFEVF, ADNFLE, BECTS, FCD, HME >40 [58–64]
MTOR FCD 18 [66, 138]
Multiple functions
ALG13 IS, LGS 4 [46, 54, 134]
EEF1A2 IS, EOEE, ASD, ID, microcephaly 4 [54–56]
PURA EOEE 15 [31, 32]
WWOX EOEE, microcephaly 8a [139–142]
ABPE atypical benign partial epilepsy, ADNFLE autosomal dominant nocturnal frontal lobe epilepsy, ASD autism spectrum disorder, BECTS benign epilepsy with
centrotemporal spikes, BFNS benign familial neonatal seizures, CAE childhood absence epilepsy, CSWS continuous spike and waves during sleep, DOORS deafness,
onychodystrophy, osteodystrophy, mental retardation and seizures syndrome, DS Dravet syndrome, EE epileptic encephalopathy, EME early myoclonic
encephalopathy, EOEE early onset epileptic encephalopathy, FE focal epilepsy, FFEVPF familial focal epilepsy with variable foci, FIME familial infantile myoclonic
epilepsy, GGE genetic generalized epilepsy, HME hemimegalencephaly, ID intellectual disability, IS infantile spasms, JME juvenile myoclonic epilepsy, LGS
Landau–Kleffner syndrome, MAE myoclonic astatic epilepsy, MPSI migrating partial seizures of infancy, NEESBs neonatal epileptic encephalopathy with suppression
bursts, OS Ohtahara syndrome, PME progressive myoclonus epilepsy.
aRefers to the number of families for recessive genes or isolated cases with respect to recurrent mutations.
bUnrelated probands have the same recurrent mutation (KCNC1 p.Arg320His), demonstrated to be de novo in 9/13.
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in chromatin remodeling and transcriptional regulation,
synaptic vesicle trafficking, and mammalian target of rapa-
mycin (mTOR) signaling.
A growing class of genes implicated in epilepsy and re-
lated disorders are those that code for proteins involved
in chromatin remodeling and transcriptional regulation.
Through targeted sequencing of candidate genes from
CNV regions, we identified 5 of 500 patients with EE
who had a de novo mutation in CHD2 [28]. This gene,
which encodes chromodomain helicase DNA-binding
protein 2, a chromatin remodeling factor, was also iden-
tified through exome sequencing in two Dravet-like cases
[44]. To date, more than 20 patients with mutations in
CHD2 have been identified, with the majority of mutations
being confirmed de novo events [28, 29, 44–47]. The epi-
lepsy phenotype is characterized by multiple seizures
types, primarily myoclonic, and exquisite photosensitivity
in most patients [29]. In addition, variants in CHD2 have
been shown to be a risk factor for photosensitivity in the
GGEs [48]. Targeted and whole-exome sequencing in a co-
hort of 580 patients with photosensitive epilepsy or photo-
paroxysmal response as determined by EEG revealed an
overrepresentation of unique, either disruptive or pre-
dicted to be damaging, variants in CHD2. The classical
photosensitive GGE—eyelid myoclonia with absences—
had the highest frequency of unique variants, with CHD2
explaining as many as 3 of 36 (8.3 %) cases. Notably, muta-
tions have also been reported in patients with autism [49]
and in ID without seizures [50]. Careful phenotyping of
additional patients with mutations in CHD2 will help de-
fine the phenotypic spectrum, which will undoubtedly be
broader than that described for the first series of patients.
CHD2 is ubiquitously expressed, and Encyclopedia of
DNA Elements (ENCODE) data suggest that it acts as a
transcriptional activator, although the target genes in the
brain are not yet known. Mechanistic studies to identify
the brain-specific function of CHD2 may yield novel drug
targets for future therapies. Another gene that causes a
surprisingly specific neural phenotype is the transcription
factor myocyte enhancer factor 2C (MEF2C). While
MEF2C has important regulatory roles in other tissue types
such as cardiac and skeletal muscle, it is a critical gene in
neural progenitor cell differentiation and maturation, and
the causative gene in 5q14 deletion syndrome. Haploinsuffi-
ciency can cause a range of features, including hyperkinesis,
variable epilepsy, ID and autism [51], as well as atypical Rett
syndrome [52, 53].
EEF1A2, which encodes the α2 subunit of eukaryotic
elongation factor 1, is another gene that merits further
investigation. Recently, de novo mutations have been
identified in four patients with severe early myoclonic
epilepsy, hypotonia and developmental delay in three dif-
ferent studies [54–56]. The canonical role of EEF1A2 istranslation elongation during protein synthesis, but di-
verse cellular functions, such as promotion of cell survival
and growth, inhibition of apoptosis, and actin cytoskeletal
remodeling via activation of the AKT pathway, have been
reported [57].
Inroads have also been made in understanding the
genetics of focal epilepsies through exome sequencing,
revealing novel pathways beyond the ion channel. Two
groups simultaneously reported mutations in DEPDC5
in patients with familial focal epilepsy with variable foci
(FFEVF) and other focal epilepsies [58, 59]. This gene
has since been implicated in various childhood focal epi-
lepsies [60] and ADNFLE [61] as well. Surprisingly, mu-
tations have been described in patients with focal
epilepsy and brain malformations, including bottom of
the sulcus dysplasia, heterotopia, focal cortical dysplasia
and hemimegalencephaly [62–64]. This is a particularly
important finding, as epilepsy due to brain malforma-
tions has often been classified as “acquired”, or non-
genetic rather than genetic, but now we must rethink
traditional classification schemes. DEPDC5 is a member
of the GATOR complex, a negative regulator of the
mTOR pathway. mTOR is a serine/threonine kinase that
converges multiple intracellular and extracellular signals
to regulate cell growth, proliferation, survival, motility
and metabolism. Dysregulation of mTOR signaling can
cause a variety of diseases, including tuberous sclerosis
(mutations in TSC1, TSC2), hemimegalencephaly (AKT3,
PIK3CA, MTOR) and focal cortical dysplasia (DEPDC5,
AKT3, MTOR) [65, 66]. Consistent neurological features of
these disorders include intractable epilepsy, ID and autistic
features, thus implicating these genes in epileptogenesis.
Exome-sequencing studies in GGE have been less suc-
cessful at identifying clear genetic risk factors or high-
penetrance mutations. In the largest study of GGE to
date, exome sequencing in 118 affected individuals and
242 controls revealed several candidate sequence variants
that were found only in affected cases [21]. However,
follow-up genotyping of 3897 candidate variants in add-
itional cases and controls failed to identify statistically
significant differences between cases and controls. Very
large cohorts may be required to make progress in GGE
due to the complex genetic architecture that likely un-
derlies this class of epilepsy.
Genetic heterogeneity
With a few exceptions, most of the novel epilepsy genes
that have been described recently are mutated in only a
handful of patients (Table 1). While the numbers of af-
fected individuals with mutations in a given gene will
undoubtedly grow as additional patients are evaluated,
it is clear that all classes of epilepsy are genetically het-
erogeneous. For the EEs, a recent, large trio exome
study highlights this point [46].
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identify de novo mutations in patients with infantile
spasms or Lennox–Gastaut syndrome (LGS) [46, 67],
two classical EEs. In a study of 264 parent–child trios, a
total of 329 de novo mutations in 305 genes were identi-
fied [46]. The majority of clearly causative mutations
were in genes already known to cause EE, including
SCN1A, STXBP1, and CDKL5, but two new disease
genes emerged: GABRB3 and ALG13. GABRB3 encodes
the β3 subunit of the GABAA receptor, supporting the
channelopathy hypothesis, while ALG13 encodes a sub-
unit of the uridine diphosphate N-acetylglucosamine
(UDP-GlcNAc) transferase that is involved in N-linked
glycosylation, an essential modification for protein fold-
ing and stability. Many candidate genes from this study
will need to be sequenced across larger cohorts to iden-
tify additional de novo mutations. This is exemplified by
the identification of DNM1 as a causative gene of EE.
The Epi4k analysis of 264 exomes identified two patients
with de novo mutations in DNM1 [46], but this number
did not reach statistical significance given the size of the
gene and predicted sequence-specific mutation rate. By
analyzing another 92 cases in collaboration with the
EuroEPINOMICS consortium, three additional de novo
mutations were identified, solidifying the pathogenic role
of mutations in DNM1 [68]. DNM1 encodes dynamin 1,
a neural-specific GTPase that localizes to the presynaptic
terminal and is important for the scission of synaptic
vesicles from the plasma membrane.
Mutations in numerous genes can also cause focal epi-
lepsy syndromes, including the recently described
DEPDC5, KCNT1 and GRIN2A genes, and a number of
genes have been identified as risk factors for or causes of
GGE. However, for both classes of epilepsy, the genes
identified to date only explain a fraction of cases, sug-
gesting that there is also considerable genetic heterogen-
eity in focal epilepsy and GGE.
Recent gene discoveries such as GABRB3, GRIN2A,
HCN1, KCNA2, and KCNH1 support the channelopathy
hypothesis, and genes that encode ion channels certainly
represent the largest class of disease-causing genes in epi-
lepsy. However, other recent gene discoveries, including
ALG13, EEF1A2, GNAO1, NECAP1, SNAP25, STX1B,
STXBP1, PURA, and WWOX, highlight that epileptogen-
esis is caused by perturbations in diverse cellular pathways
(Table 1), providing further evidence that epilepsy is not
explained wholly as a channelopathy.
Expanding the phenotypic spectrum
There is an increasingly wide phenotypic spectrum asso-
ciated with mutations in GABRA1, KCNQ2, KCNT1,
SCN8A, TBC1D24, and DEPDC5. Genetic modifiers and/
or environmental risk factors may influence the epilepsy
subtype or severity; this will require more systematicstudies in the future. Careful experiments evaluating the
functional consequences of specific dominant mutations
are beginning to explain some of these differences [69–71].
A recent example comes from the potassium channel sub-
unit Kv7.2, encoded by KCNQ2, in which alterations at
the same amino acid (p.Arg213Trp and p.Arg213Gln) lead
to strikingly different phenotypes [69]. The Arg213Trp
change caused benign familial neonatal seizures, a domin-
antly inherited neonatal epilepsy with a generally favorable
prognosis, in contrast to the Arg213Gln change, which
caused neonatal EE with severe pharmacoresistant seizures,
EEG consistent with a burst-suppression pattern, macro-
cephaly, and neurocognitive and motor delays [69, 72].
Miceli and colleagues demonstrated that both mutations in
the potassium channel subunit Kv7.2 caused a decrease in
channel voltage sensitivity, but the Arg213Gln mutation
had a more dramatic effect, likely explaining the more
severe phenotype. Detailed mutation modeling such as this
will be required to understand how molecular perturbations
underlie the etiology of epilepsy syndromes.
For some genes, the phenotypic spectrum expands be-
yond the epilepsies to other neurodevelopmental disor-
ders, including autism and ID. For example, although the
majority of patients with mutations in STXBP1, SYN-
GAP1, or CHD2 present with seizures, mutations have
also been identified in individuals with ID and/or autism
spectrum disorder but without epilepsy [49]. Mutations
in SCN1A have been found in patients from autism co-
horts [73], and mutations in SCN2A cause a range of
neurodevelopmental conditions with and without sei-
zures [74]. It is important to remember that there may
be selection and phenotyping bias in large cohorts; that
is, phenotype information for patients recruited to “aut-
ism” studies will focus on autistic features and subtypes
whereas patients in “epilepsy” cohorts will likely have de-
tailed seizure and EEG information available. Careful and
comprehensive phenotyping of patients after a mutation
is identified will help determine the full phenotypic
spectrum associated with a given mutation within a gene,
without such phenotypic bias.
Where are the missing mutations?
Genomic technologies have afforded tremendous pro-
gress in understanding the genetics of epilepsy, but there
is still much work to be done. Despite whole-exome se-
quencing in trios, a large number of cases of EE remain
unsolved. The combined Epi4K/EuroEPINOMICS study
conservatively estimates that trio sequencing provided a
clear genetic etiology in up to ~12 % of 356 samples.
Most cases had at least one de novo coding variant; for a
subset of cases, the de novo variant may be causative, al-
though this is difficult to prove without additional cases
or functional studies. Recessive mutations may explain a
minority of cases but are more likely in families where
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mutations are increasingly recognized as an important
cause of disease across a range of disorders. In the epi-
lepsies, many of the mutations in the mTOR pathway
that have been found in patients with brain malforma-
tions are somatic mosaic mutations [75–77]. Individuals
with somatic mutations may present with variable phe-
notypes and severity depending on how many and which
cells carry the mutation. Importantly, somatic mosaic
mutations are not always detectable in DNA from blood,
although increasingly low levels of mosaicism can be de-
tected through deep next-generation sequencing [76]. In
some cases, the mutation may be present only in the af-
fected tissue, which will be difficult to obtain for many
epilepsies. Resection of affected tissue in focal epilepsies
may shed light on how this mechanism may help define
the role of mosaic mutations in epilpesy. Finally, a largely
unexplored area is the impact of mutations in non-
exonic DNA. Rare noncoding mutations have been iden-
tified in some human diseases and are likely to play a
role in epilepsy as well. Whole-genome sequencing in
trios will reveal candidate de novo variants for further
exploration of this hypothesis. Sorting out the complex
genetics of GGE will likely require much larger cohorts
and families to understand the combination of factors
that contribute to genetic risk.
Clinical implications
Establishing the genetic basis of epilepsy in a given patient
is important for counseling with respect to disease progno-
sis, for determining recurrence risk for future pregnancies
and for treatment decisions in select cases [78]. A genetic
diagnosis ends the diagnostic odyssey and eliminates un-
necessary medical tests, and can provide the family with
the opportunity to identify others in a similar situation
and connect with support groups. There has been a recent
growth in family organizations for the EEs, such as the
Dravet Foundation, LGS Foundation, PCDH19 Alliance,
Jack Pribaz Foundation (for those with KCNQ2mutations)
and FAMILIEScn2A (SCN2A mutations), among others.
These organizations are powerful patient advocates, pro-
viding information and support to affected families; in
addition, some family organizations play an important role
in funding research.
The genetic heterogeneity of epilepsy influences gen-
etic testing, as testing one gene at a time is no longer a
practical approach. The development of gene panels and
the introduction of exome sequencing for clinical diag-
nostics now provide more comprehensive and affordable
options for testing and should be implemented early in
the diagnostic process. Chromosome microarrays should
be considered in severe cases and in GGE with co-
morbid features, where the likelihood of finding a
disease-associated CNV is highest.Beyond diagnostics, a major goal of genetic studies is
to identify novel drug targets and to be able to make
treatment choices based on the genetic cause of disease
—an approach termed precision medicine. This will not
be a simple task given the genetic complexity of epilepsy,
in which mutations in different genes cause syndromes
that are clinically indistinguishable, and mutations in a sin-
gle gene, such as SCN1A, can cause a range of phenotypes
varying from febrile seizures to severe EEs. However, re-
cent reports offer the first insights into the power of preci-
sion medicine in treating epilepsy [79, 80]. Exome
sequencing identified a heterozygous missense mutation
in KCNT1 (c.1283G >A; p.Arg428Gln) in a child with mi-
grating partial seizures of infancy (MPSI); the same muta-
tion had been previously reported in three other patients
with MPSI. Functional studies in Xenopus oocytes demon-
strated that the mutant protein caused a hyperactive chan-
nel [81], and that the effects of the mutation could be
partially reversed by quinidine, an antiarrhythmic drug
that is a partial antagonist of the potassium channel
encoded by KCNT1 [70, 82]. Administration of oral
quinidine in this child correlated with diminished or
absent seizure activity and an improvement in psycho-
motor skills. Similarly, the administration of meman-
tine, a US Food and Drug Administration-approved
NMDA (N-methyl-D-aspartate) receptor antagonist,
greatly reduced seizure activity in a patient with early
onset EE caused by a de novo missense mutation in
GRIN2A (p.Leu812Met) [80]. In vitro experiments
testing for activity of the mutant receptor were per-
formed prior to administration of the drug, an im-
portant point as not all mutations affect a protein
equally. In vitro experiments performed on another
GRIN2A mutant protein (p.Asn615Lys), which was
the genetic cause of another child’s early onset EE,
demonstrated that this mutation had a different effect
on protein function entirely. GRIN2A encodes a sub-
unit of the NMDA receptor, which is an ion channel
that is activated by glutamate. Under normal conditions
of synaptic transmission, very few ions pass through the
channel because Mg2+ blocks the pore. Upon receptor ac-
tivation, Mg2+ is displaced, which allows Ca2+ and other
cations to move into the cell. A dysfunctional NMDA re-
ceptor can cause excess calcium influx into the cell and
neurotoxicity. The Leu812Met change caused a hyper-
active receptor, while the Asn615Lys mutation had no ef-
fect on receptor activity and acted through loss of the Mg2
+ block. Although both mutations resulted in an increased
flow of current, leading to excessive excitatory drive and
early onset EE, it was important to consider the different
pathological mechanisms and drug targets when deciding
treatment options.
These studies highlight the importance of obtaining a
molecular diagnosis early in development when possible,
Myers and Mefford Genome Medicine  (2015) 7:91 Page 8 of 11the use of cell culture and animal models to aid in the
interpretation of the functional consequences of a muta-
tion, and the need for rigorous clinical trials to
standardize dosing and evaluate potential side effects of
treatment. Other monogenic epilepsies for which a mo-
lecular diagnosis may influence the choice of anti-
epileptic drugs are KCNQ2-related epilepsies and the use
of ezogabine [83, 84], SCN1A-related Dravet syndrome
and the use of clemizole [85], and DEPDC5 and the use
of the rapamycin derivative everolimus, which has
already been effective in early clinical trials [86].
Conclusions and future directions
Advances in DNA sequencing and interpretation of gen-
etic variation are rapidly changing our understanding of
the causes of epilepsy and its clinical management. It is
unlikely that an individual gene will explain a large pro-
portion of the GGEs, so efforts should be made to se-
quence large cohorts to gain broad insight into the
mechanisms of epileptogenesis. Exome sequencing of
trios has revealed the prominence of de novo mutations
as a genetic cause of severe epilepsies, indicating that
even in the absence of a family history, a genetic cause
should be considered. Another important point to be
taken away from the next-generation sequencing experi-
ments is the diverse classes of genes that are emerging as
being implicated in epilepsy. The recent surge of novel
findings moves beyond the channelopathy hypothesis,
implicating pathways that regulate synaptic vesicle traf-
ficking, mTOR signaling, chromatin remodeling and tran-
scriptional regulation, which offer new insights into
disease-causing mechanisms and provide novel avenues
for therapeutics. Despite recent advances, there are many
genetic mysteries that remain to be unraveled. As whole-
genome sequencing becomes more prevalent, the pace of
discovery is likely to accelerate once again. Collabora-
tions that include large cohorts and the sharing of re-
search data will expedite gene discovery across all types
of epilepsy, and central repositories for large-scale se-
quencing projects and epilepsy-specific findings will aid
in the interpretation of rare variations. Finally, central-
ized variant databases and streamlined approaches to
functional studies will move the field closer to translating
genetic discoveries to directed therapies as we enter the
era of precision medicine.
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